Compounds > temozolomide
Page last updated: 2024-08-16

temozolomide and nu 1025

temozolomide has been researched along with nu 1025 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Boulton, S; Durkacz, BW; Kyle, S1
Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW1
Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G1
Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J1
Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ1

Other Studies

5 other study(ies) available for temozolomide and nu 1025

ArticleYear
Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
    Carcinogenesis, 1999, Volume: 20, Issue:2

    Topics: Androstadienes; Animals; Antineoplastic Agents; Cell Survival; CHO Cells; Cricetinae; Dacarbazine; DNA; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; DNA, Single-Stranded; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Quinazolines; Temozolomide; Wortmannin

1999
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay

2000
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
    Blood, 2002, Mar-15, Volume: 99, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Survival Analysis; Survival Rate; Temozolomide

2002
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Oncology, 2010, Volume: 78, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay

2010
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Oncology reports, 2020, Volume: 44, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mutation; Poly (ADP-Ribose) Polymerase-1; PTEN Phosphohydrolase; Quinazolines; Temozolomide; Tumor Suppressor Proteins

2020